Fulgent Genetics, Inc. (FLGT)
| Market Cap | 663.27M -4.9% |
| Revenue (ttm) | 330.28M +4.7% |
| Net Income | -90.93M |
| EPS | -3.10 |
| Shares Out | 27.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,097,522 |
| Open | 20.47 |
| Previous Close | 18.66 |
| Day's Range | 19.64 - 23.85 |
| 52-Week Range | 13.46 - 31.04 |
| Beta | 1.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About FLGT
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he... [Read more]
Financial Performance
In 2025, Fulgent Genetics's revenue was $322.67 million, an increase of 13.83% compared to the previous year's $283.47 million. Losses were -$60.51 million, 41.7% more than in 2024.
Financial StatementsNews
Fulgent Genetics reports Q3 EPS (48c) vs. (21c) last year
Reports Q3 revenue $90.4M vs. $84.1M last year. Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, “We are encouraged by the momentum in our therapeutics…
Fulgent Genetics sees FY26 EPS ($1.75) to ($1.65), consensus ($2.27)
Sees FY26 revenue $330M-$340M, one estimate $331.7M
Fulgent Genetics Earnings Call Transcript: Q3 2026
Q3 revenue grew 8% YoY as Bako and StrataDx integration and improving collections supported sequential gains; losses narrowed, and FY 2026 non-GAAP loss guidance improved. Billing-system work and below-historical collections remain important factors.
Fulgent Genetics Earnings release: Q3 2026
Fulgent Genetics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Fulgent Genetics Quarterly report: Q3 2026
Fulgent Genetics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Fulgent Genetics Slides: Q3 2026
Fulgent Genetics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Fulgent Reports Third Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics price target raised to $19 from $15 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Fulgent Genetics (FLGT) to $19 from $15 following quarterly results. The firm keeps a Neutral rating on the shares.
Fulgent Genetics reports Q2 adjusted EPS (58c), two estimates (44c)
Reports Q2 revenue $85.4M, two estimates $91.77M. Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, “In the second quarter, we had the honor of presenting…
Fulgent Genetics cuts FY26 adjusted EPS view to ($2.35)-($2.22) from ($1.59)
Two estimates ($1.57). Cuts FY26 revenue view to $330M-$340M from $350M, two estimates $350.93M.
Fulgent Genetics Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 4% year-over-year to $85.4 million, driven by acquisitions, but billing system transition reduced collection rates and margins. Full-year revenue guidance was lowered to $330–$340 million, with continued investment in R&D and digital pathology.
Fulgent Genetics Earnings release: Q2 2026
Fulgent Genetics released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Fulgent Genetics Slides: Q2 2026
Fulgent Genetics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Fulgent Genetics Quarterly report: Q2 2026
Fulgent Genetics has published its Q2 2026 quarterly earnings report on July 30, 2026.
Fulgent Reports Second Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics presents updated FID-007 data at ASCO 2026
Fulgent Genetics (FLGT) “announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session,…
Fulgent Presents Updated FID-007 Data at ASCO 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development busin...
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Com...
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). The investigation focuses on Fulgent...
Fulgent Genetics price target lowered to $15 from $30 at Piper Sandler
Piper Sandler lowered the firm’s price target on Fulgent Genetics (FLGT) to $15 from $30 following quarterly results. The firm keeps a Neutral rating on the shares. Published first on…
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.
Fulgent Genetics Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined due to a major customer transition, but acquisitions and new product launches are expected to drive growth. Guidance for 2026 is reaffirmed, with improved margins and reduced customer concentration risk anticipated.